Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants

Hee Jeong Cho, Ji Yeon Kim, Youngsik Lee, Jung Mogg Kim, Young Bong Kim, Taehoon Chun, Yu Kyoung Oh

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Needle-free nonparenteral vaccines offer a number of practical advantages, especially in developing countries. To address the effects of vaccine administration route, we tested mucosal and systemic immune responses against human papillomavirus 16 L1(HPV16L1) protein using intranasal, intravaginal, transdermal, sublingual (SL) and intramuscular routes. The SL route provided the most effective mucosal secretory IgA (sIgA) and serum IgG responses. After a 150 μg antigen dose via the SL route, saliva sIgA levels were 7.2- and 5.8-fold higher than those achieved via intravaginal and transdermal routes, respectively. Notably, SL administration even produced 4.6-fold higher levels of vaginal sIgA levels than did intravaginal delivery of 150 μg antigen. To enhance the immunogenicity of SL vaccines, we tested the adjuvanticity of nine molecules: three toll-like receptor agonists, three nucleotide-binding oligomerization-domain agonists, vitamin D3, poly-γ-glutamic acid and cholera toxin subunit B (CTB). Among the molecules tested, CTB provided the most enhanced mucosal sIgA and systemic IgG induction. SL-applied CTB enhanced the production of interleukin-4 and interferon-γ from stimulated CD4+ T cells. Moreover, interferon-γ-producing CD8+ T cell responses were increased 1.7-fold after co-treatment with SL CTB and HPV16L1. These results suggest the potential of the SL route for delivery of HPV16L1 vaccines using CTB as an adjuvant.

Original languageEnglish
Pages (from-to)2598-2606
Number of pages9
JournalVaccine
Volume28
Issue number14
DOIs
Publication statusPublished - 2010 Mar 19

Fingerprint

Human papillomavirus 16
cholera toxin
Cholera Toxin
Humoral Immunity
Secretory Immunoglobulin A
humoral immunity
Cellular Immunity
cell-mediated immunity
adjuvants
Immunization
immunization
vaccines
Vaccines
interferons
proteins
Interferons
agonists
T-lymphocytes
Immunoglobulin G
polyglutamic acid

Keywords

  • Human papillomavirus
  • Mucosal vaccination
  • Sublingual adjuvant
  • Sublingual route

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. / Cho, Hee Jeong; Kim, Ji Yeon; Lee, Youngsik; Kim, Jung Mogg; Kim, Young Bong; Chun, Taehoon; Oh, Yu Kyoung.

In: Vaccine, Vol. 28, No. 14, 19.03.2010, p. 2598-2606.

Research output: Contribution to journalArticle

Cho, Hee Jeong ; Kim, Ji Yeon ; Lee, Youngsik ; Kim, Jung Mogg ; Kim, Young Bong ; Chun, Taehoon ; Oh, Yu Kyoung. / Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. In: Vaccine. 2010 ; Vol. 28, No. 14. pp. 2598-2606.
@article{a7797abfcdc34475b4768c3e3a74d9de,
title = "Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants",
abstract = "Needle-free nonparenteral vaccines offer a number of practical advantages, especially in developing countries. To address the effects of vaccine administration route, we tested mucosal and systemic immune responses against human papillomavirus 16 L1(HPV16L1) protein using intranasal, intravaginal, transdermal, sublingual (SL) and intramuscular routes. The SL route provided the most effective mucosal secretory IgA (sIgA) and serum IgG responses. After a 150 μg antigen dose via the SL route, saliva sIgA levels were 7.2- and 5.8-fold higher than those achieved via intravaginal and transdermal routes, respectively. Notably, SL administration even produced 4.6-fold higher levels of vaginal sIgA levels than did intravaginal delivery of 150 μg antigen. To enhance the immunogenicity of SL vaccines, we tested the adjuvanticity of nine molecules: three toll-like receptor agonists, three nucleotide-binding oligomerization-domain agonists, vitamin D3, poly-γ-glutamic acid and cholera toxin subunit B (CTB). Among the molecules tested, CTB provided the most enhanced mucosal sIgA and systemic IgG induction. SL-applied CTB enhanced the production of interleukin-4 and interferon-γ from stimulated CD4+ T cells. Moreover, interferon-γ-producing CD8+ T cell responses were increased 1.7-fold after co-treatment with SL CTB and HPV16L1. These results suggest the potential of the SL route for delivery of HPV16L1 vaccines using CTB as an adjuvant.",
keywords = "Human papillomavirus, Mucosal vaccination, Sublingual adjuvant, Sublingual route",
author = "Cho, {Hee Jeong} and Kim, {Ji Yeon} and Youngsik Lee and Kim, {Jung Mogg} and Kim, {Young Bong} and Taehoon Chun and Oh, {Yu Kyoung}",
year = "2010",
month = "3",
day = "19",
doi = "10.1016/j.vaccine.2010.01.013",
language = "English",
volume = "28",
pages = "2598--2606",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "14",

}

TY - JOUR

T1 - Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants

AU - Cho, Hee Jeong

AU - Kim, Ji Yeon

AU - Lee, Youngsik

AU - Kim, Jung Mogg

AU - Kim, Young Bong

AU - Chun, Taehoon

AU - Oh, Yu Kyoung

PY - 2010/3/19

Y1 - 2010/3/19

N2 - Needle-free nonparenteral vaccines offer a number of practical advantages, especially in developing countries. To address the effects of vaccine administration route, we tested mucosal and systemic immune responses against human papillomavirus 16 L1(HPV16L1) protein using intranasal, intravaginal, transdermal, sublingual (SL) and intramuscular routes. The SL route provided the most effective mucosal secretory IgA (sIgA) and serum IgG responses. After a 150 μg antigen dose via the SL route, saliva sIgA levels were 7.2- and 5.8-fold higher than those achieved via intravaginal and transdermal routes, respectively. Notably, SL administration even produced 4.6-fold higher levels of vaginal sIgA levels than did intravaginal delivery of 150 μg antigen. To enhance the immunogenicity of SL vaccines, we tested the adjuvanticity of nine molecules: three toll-like receptor agonists, three nucleotide-binding oligomerization-domain agonists, vitamin D3, poly-γ-glutamic acid and cholera toxin subunit B (CTB). Among the molecules tested, CTB provided the most enhanced mucosal sIgA and systemic IgG induction. SL-applied CTB enhanced the production of interleukin-4 and interferon-γ from stimulated CD4+ T cells. Moreover, interferon-γ-producing CD8+ T cell responses were increased 1.7-fold after co-treatment with SL CTB and HPV16L1. These results suggest the potential of the SL route for delivery of HPV16L1 vaccines using CTB as an adjuvant.

AB - Needle-free nonparenteral vaccines offer a number of practical advantages, especially in developing countries. To address the effects of vaccine administration route, we tested mucosal and systemic immune responses against human papillomavirus 16 L1(HPV16L1) protein using intranasal, intravaginal, transdermal, sublingual (SL) and intramuscular routes. The SL route provided the most effective mucosal secretory IgA (sIgA) and serum IgG responses. After a 150 μg antigen dose via the SL route, saliva sIgA levels were 7.2- and 5.8-fold higher than those achieved via intravaginal and transdermal routes, respectively. Notably, SL administration even produced 4.6-fold higher levels of vaginal sIgA levels than did intravaginal delivery of 150 μg antigen. To enhance the immunogenicity of SL vaccines, we tested the adjuvanticity of nine molecules: three toll-like receptor agonists, three nucleotide-binding oligomerization-domain agonists, vitamin D3, poly-γ-glutamic acid and cholera toxin subunit B (CTB). Among the molecules tested, CTB provided the most enhanced mucosal sIgA and systemic IgG induction. SL-applied CTB enhanced the production of interleukin-4 and interferon-γ from stimulated CD4+ T cells. Moreover, interferon-γ-producing CD8+ T cell responses were increased 1.7-fold after co-treatment with SL CTB and HPV16L1. These results suggest the potential of the SL route for delivery of HPV16L1 vaccines using CTB as an adjuvant.

KW - Human papillomavirus

KW - Mucosal vaccination

KW - Sublingual adjuvant

KW - Sublingual route

UR - http://www.scopus.com/inward/record.url?scp=77649179585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649179585&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.01.013

DO - 10.1016/j.vaccine.2010.01.013

M3 - Article

C2 - 20116467

AN - SCOPUS:77649179585

VL - 28

SP - 2598

EP - 2606

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 14

ER -